| 초록 |
In a proof-of-concept, PNA captures dsDNA based on complementary region occurring in solution or in solid phase and methyl-CpG binding domain proteins 2 (MBD2) tightly binds to mCpG on ds DNA without A/T sequence adjacent to mCpG in vitro and in vivo. We developed a novel platform to (i) simultaneously detect two complementary target biomarkers: natural P53 methylation and MBD2, a crucial tumor biomarker, in one real sample, and (ii) follow-up and evaluate real-world epigenetics-driven transcriptional repression using nanoplasmonic biosensor. As the most sensitive plasmonic properties, gold nanostars (45 nm) were exploited as platform to measure the localized surface plasmonic resonance (LSPR) spectral shifting to the redder region. For sensitivity assay, we recorded the LSPR λmax shifts 15.7 nm corresponding to one mCpG on dsP53 and using 125 aM MBD2. |
